These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 32737466)

  • 41. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
    Konwarh R
    Front Immunol; 2020; 11():1531. PubMed ID: 32655584
    [No Abstract]   [Full Text] [Related]  

  • 43. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
    Wrapp D; Wang N; Corbett KS; Goldsmith JA; Hsieh CL; Abiona O; Graham BS; McLellan JS
    Science; 2020 Mar; 367(6483):1260-1263. PubMed ID: 32075877
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
    Ou X; Liu Y; Lei X; Li P; Mi D; Ren L; Guo L; Guo R; Chen T; Hu J; Xiang Z; Mu Z; Chen X; Chen J; Hu K; Jin Q; Wang J; Qian Z
    Nat Commun; 2020 Mar; 11(1):1620. PubMed ID: 32221306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
    Wrobel AG; Benton DJ; Hussain S; Harvey R; Martin SR; Roustan C; Rosenthal PB; Skehel JJ; Gamblin SJ
    Nat Commun; 2020 Oct; 11(1):5337. PubMed ID: 33087721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
    Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
    Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
    [No Abstract]   [Full Text] [Related]  

  • 50. Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD.
    Errico JM; Zhao H; Chen RE; Liu Z; Case JB; Ma M; Schmitz AJ; Rau MJ; Fitzpatrick JAJ; Shi PY; Diamond MS; Whelan SPJ; Ellebedy AH; Fremont DH
    Cell Rep; 2021 Oct; 37(4):109881. PubMed ID: 34655519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
    Corrêa Giron C; Laaksonen A; Barroso da Silva FL
    Virus Res; 2020 Aug; 285():198021. PubMed ID: 32416259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
    Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
    [No Abstract]   [Full Text] [Related]  

  • 53. Structure and inhibition of SARS-CoV-2 spike refolding in membranes.
    Grunst MW; Qin Z; Dodero-Rojas E; Ding S; Prévost J; Chen Y; Hu Y; Pazgier M; Wu S; Xie X; Finzi A; Onuchic JN; Whitford PC; Mothes W; Li W
    Science; 2024 Aug; 385(6710):757-765. PubMed ID: 39146425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.
    Tortorici MA; Beltramello M; Lempp FA; Pinto D; Dang HV; Rosen LE; McCallum M; Bowen J; Minola A; Jaconi S; Zatta F; De Marco A; Guarino B; Bianchi S; Lauron EJ; Tucker H; Zhou J; Peter A; Havenar-Daughton C; Wojcechowskyj JA; Case JB; Chen RE; Kaiser H; Montiel-Ruiz M; Meury M; Czudnochowski N; Spreafico R; Dillen J; Ng C; Sprugasci N; Culap K; Benigni F; Abdelnabi R; Foo SC; Schmid MA; Cameroni E; Riva A; Gabrieli A; Galli M; Pizzuto MS; Neyts J; Diamond MS; Virgin HW; Snell G; Corti D; Fink K; Veesler D
    Science; 2020 Nov; 370(6519):950-957. PubMed ID: 32972994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
    Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
    Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
    Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.